ArticleAbdominal radiology (New York)2025
Preliminary study on determining the optimal position of region of interest for evaluating hepatic steatosis using ultrasound Attenuation imaging.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo find the optimal position of region of interest (ROI) for evaluating hepatic steatosis using attenuation imaging (ATI) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).
methodsWe retrospectively enrolled 143 consecutive patients who underwent percutaneous liver biopsy for the evaluation of MAFLD between October 2020 and October 2022. All ATI measurements were performed by the same radiologist. The ATI-ROI was placed at four different positions using a specialized workstation: the top edge of the sampling box (P1), the lower edge of the dark orange region (P2), 0.5 cm and 1 cm below the lower edge of the dark orange region (P3 and P4). Multivariate linear regression analysis and the area under the curve (AUC) analysis were performed.
resultsThe AUCs of ATI at the four different ATI-ROI positions were 0.472 (95% confidence interval [CI]: 0.362-0.581), 0.693(0.611-0.768), 0.757(0.611-0.768), and 0.809 (0.735-0.870) for ≥ S1; 0.544 (0.459-0.628), 0.779 (0.702-0.844), 0.842 (0.772-0.898), and 0.865 (0.798-0.916) for ≥ S2; and 0.655 (0.571-0.733), 0.904 (0.843-0.947), 0.95 (0.9-0.979), and 0.949 (0.9-0.979) for S3, respectively. The factor that most significantly affected ATI was steatosis grade(P<0.001), when ATI-ROI was placed at the position of P2, P3, and P4.
conclusionHepatic steatosis grade was the most significant determinant factor for ATI value at multivariate analysis. When clinicians conduct ATI measurement, the dark orange region indicating the area of reverberation artifact should be avoided, and placing the ATI-ROI 1 cm below the lower edge of the dark orange region may be a better choice.
Indexed as
Identifiers
40095021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.